Search

everythinglearnresearchcommunity

for

Search:↓

The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The user is excited about starting Clascoterone 5% for hair loss, a DHT blocker, and expects better results when combined with Minoxidil. The prescription costs $199 for 30 ml or $353 for 60 ml, and the user plans to cover the cost by driving for Uber.

The user is asking about the effectiveness of tretinoin 0.025% for hair loss, noting significant beard growth since using it for acne. They are considering adding it to their hair loss treatment regimen.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.

The user received a Fagron TrichoTest indicating that Finasteride, Dutasteride, and Minoxidil are not effective for them, recommending Latanoprost, Spironolactone, IGrantine-F1 TM, and Trichoxidil instead. Other users expressed skepticism about the test's validity and suggested sticking with proven treatments like Finasteride and Dutasteride.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

The conversation discusses the difficulty of applying tretinoin 0.025% cream on the scalp and considers switching to a gel for easier application. It also mentions that a liquid solution, ideally combined with minoxidil, may be more effective for hair treatment.

The post discusses a hair loss treatment regimen using saw palmetto, pumpkin seed oil extract, EGCG (green tea) extract, grape seed oil extract, rosemary oil extract, and Zix. The user plans to use these DHT-blockers and 5AR inhibitors for six months and report the results.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

The user started a hair loss treatment with a topical solution containing 0.1% Dutasteride, 7.5% Minoxidil, 0.0125% Tretinoin, and Biotin, along with a multivitamin, Ashwagandha, CBD oil, Retinol, and Caffeine Solution. They experienced some shedding and scalp irritation, leading to a reduction in the use of the caffeine solution.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

A 25-year-old male experienced increased testosterone and estradiol levels after starting finasteride for hair loss, leading his doctor to suggest a testicular ultrasound as a precaution. The user questions the necessity of the ultrasound, considering it potentially excessive, while others suggest it could be a useful precaution to rule out any issues.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

A user reported a 50% increase in testosterone after 18 months of taking dutasteride for hair loss. The conversation includes skepticism about the reliability of single testosterone tests and questions about estrogen levels.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.